Lytix Biopharma is a clinical-stage biotech company with a highly novel technology platform using host-defense peptide-derived molecules to kill cancer cells and kick start the immune system. The Company was listed on Euronext Growth in Oslo in June 2021 (Euronext Growth Oslo: LYTIX).

Please follow Lytix Biopharma's stock announcements by registering your email address here.